OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Till on the Durability of Response With Brexucabtagene Autoleucel in MCL

March 16th 2021

Brian Till, MD, discusses the potential durability of brexucabtagene autoleucel in mantle cell lymphoma.

Dr. Atkins on the FDA Approval of Tivozanib in Relapsed/Refractory Advanced RCC

March 16th 2021

Michael B. Atkins, MD, discusses the FDA approval of tivozanib in relapsed/refractory advanced renal cell carcinoma.

Dr. Martin on the Utility of Aggressive Frontline Treatment in Multiple Myeloma

March 15th 2021

Thomas G. Martin, MD, discusses the utility of aggressive frontline treatment in multiple myeloma.

Dr. Goy on Next Steps With CAR T-Cell Therapy in MCL

March 12th 2021

Andre Goy, MD, discusses the next steps with CAR T-cell therapy in mantle cell lymphoma.

Dr. Kumar on the Challenges of Selecting Therapy in Heavily Pretreated Multiple Myeloma

March 12th 2021

Shaji K. Kumar, MD, discusses the challenges of selecting therapy for patients with heavily pretreated multiple myeloma.

Dr. Mead on the Role of BTK Inhibition After Venetoclax in Relapsed/Refractory CLL

March 12th 2021

Monica D. Mead, MD, discusses the role of BTK inhibition after venetoclax in relapsed/refractory chronic lymphocytic leukemia.

Dr. Philip on Non-Operative Treatment Advances in CRC

March 12th 2021

Tony Philip, MD, discusses advances made in the treatment of patients with colorectal cancer.

Dr. Kazmi on Choosing Among Regorafenib and TAS-102 in Metastatic CRC

March 11th 2021

Syed Kazmi, MD, discusses choosing among regorafenib and TAS-102 in the treatment of patients with metastatic colorectal cancer.

Dr. Bociek on the Role of MRD in CLL

March 11th 2021

R. Gregory Bociek, MD, discusses the role of minimal residual disease in patients with chronic lymphocytic leukemia.

Dr. Au on the Rationale to Evaluate Antiviral Immunity From COVID-19 in Cancer

March 11th 2021

Lewis Au, MBBS, BMedSci, FRACP, discusses the rationale to evaluate antiviral immunity from COVID-19 among patients with cancer.

Dr. Richardson on the Toxicity Profile of Melphalan Flufenamide in Multiple Myeloma

March 11th 2021

Paul G. Richardson, MD, discusses the toxicity profile of melphalan flufenamide in relapsed/refractory multiple myeloma.

Dr. Martin on the Importance of Developing Novel Therapies in MCL

March 11th 2021

Peter Martin, MD, discusses the importance of developing novel therapies in mantle cell lymphoma.

Dr. Basu-Mallick on Selecting Frontline HER2-Directed Therapy in CRC

March 10th 2021

Atrayee Basu-Mallick, MD, discusses factors to consider when selecting a frontline HER2-directed treatment regimen for patients with colorectal cancer.

Dr. Longshore on Key Molecular Markers in Metastatic Lung Cancer

March 10th 2021

John Longshore, PhD, FACMG, discusses key molecular markers in metastatic lung cancer.

Dr. Boyle on the Role of Concurrent Molecular Testing in Lung Cancer

March 10th 2021

Theresa Boyle, MD, PhD, discusses the role of concurrent molecular testing in lung cancer.

Dr. Goy on the Efficacy of Brexucabtagene Autoleucel in Relapsed/Refractory MCL

March 10th 2021

Andre Goy, MD, discusses the efficacy of brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma, as demonstrated in the phase 2 ZUMA-2 trial.

Dr. Pillai on the Importance of Multidisciplinary Discussion in HCC

March 10th 2021

Anjana Pillai, MD, discusses the importance of multidisciplinary discussion in hepatocellular carcinoma.

Dr. Neelapu on Managing Toxicities Associated with CAR T-Cell Products in Lymphoma

March 10th 2021

Sattva Neelapu, MD, discusses the management of toxicities associated with CAR T-cell products in patients with lymphoma.

Dr. Usmani on the Potential Utility of Allogeneic CAR T-Cell Therapy in Multiple Myeloma

March 9th 2021

Saad Z. Usmani, MD, FACP, discusses the potential utility of allogeneic CAR T-cell therapy in multiple myeloma.

Dr. Philip on the Emerging Role of ctDNA in CRC

March 9th 2021

Tony Philip, MD, discusses the emerging role of circulating tumor DNA in colorectal cancer.